Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-7.36 Insider Own30.22% Shs Outstand28.15M Perf Week-14.48%
Market Cap93.27M Forward P/E- EPS next Y-2.33 Insider Trans0.00% Shs Float21.20M Perf Month9.25%
Income-211.60M PEG- EPS next Q-0.92 Inst Own30.85% Short Float11.58% Perf Quarter-21.28%
Sales1.24M P/S75.21 EPS this Y0.29% Inst Trans-5.59% Short Ratio1.58 Perf Half Y-23.82%
Book/sh-1.39 P/B- EPS next Y60.59% ROA-122.57% Short Interest2.46M Perf Year-89.27%
Cash/sh2.96 P/C1.04 EPS next 5Y- ROE-489.95% 52W Range1.91 - 32.87 Perf YTD4.07%
Dividend Est.- P/FCF- EPS past 5Y-84.64% ROI-358.57% 52W High-90.66% Beta0.42
Dividend TTM- Quick Ratio2.45 Sales past 5Y0.00% Gross Margin23.59% 52W Low60.73% ATR (14)0.42
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM-50.24% Oper. Margin-16036.72% RSI (14)49.05 Volatility9.43% 15.40%
Employees183 Debt/Eq- Sales Y/Y TTM806.57% Profit Margin-17037.44% Recom2.00 Target Price9.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-15.62% Payout- Rel Volume0.86 Prev Close3.17
Sales Surprise-45.53% EPS Surprise-35.02% Sales Q/Q148.91% EarningsNov 14 BMO Avg Volume1.56M Price3.07
SMA20-5.14% SMA501.47% SMA200-59.90% Trades Volume1,346,242 Change-3.15%
Date Action Analyst Rating Change Price Target Change
Feb-21-24Downgrade UBS Buy → Neutral $9 → $4
Aug-15-23Downgrade Mizuho Buy → Neutral $40 → $4
Jul-17-23Downgrade Guggenheim Buy → Neutral
Mar-10-23Downgrade Jefferies Buy → Hold $20 → $22
Dec-01-22Upgrade Goldman Sell → Neutral $16
Jul-07-22Initiated Mizuho Buy $19
Apr-06-22Reiterated BofA Securities Buy $80
Nov-15-21Downgrade Goldman Neutral → Sell $55 → $24
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Feb-22-24 12:58PM
Feb-14-24 08:30AM
Feb-13-24 09:00AM
Feb-12-24 07:14AM
Feb-09-24 09:05AM
04:01PM Loading…
Feb-08-24 04:01PM
Feb-06-24 07:00AM
Feb-05-24 07:00AM
Dec-12-23 07:00AM
Dec-11-23 07:00AM
Dec-01-23 07:29PM
Nov-30-23 07:00AM
Nov-24-23 06:40AM
Nov-15-23 02:23PM
07:52AM Loading…
Nov-14-23 07:52AM
Nov-08-23 07:00AM
Nov-06-23 07:00AM
Oct-31-23 07:00AM
Oct-30-23 07:00AM
Oct-25-23 09:18AM
Oct-17-23 10:26AM
Oct-10-23 09:45AM
Oct-04-23 07:00AM
Sep-28-23 05:35PM
Aug-29-23 07:30AM
Aug-17-23 10:30AM
05:43PM Loading…
Aug-15-23 05:43PM
Aug-14-23 11:04PM
Jul-31-23 07:00AM
Jul-07-23 08:16AM
Jul-05-23 10:20AM
Jun-29-23 04:12PM
Jun-15-23 09:46PM
Jun-02-23 06:20AM
Jun-01-23 07:00AM
May-25-23 04:03PM
May-16-23 07:00AM
May-11-23 03:13PM
May-09-23 02:03AM
May-08-23 04:54PM
May-04-23 08:00AM
May-02-23 07:00AM
Apr-24-23 07:00AM
Mar-22-23 08:21AM
Mar-14-23 04:15PM
Mar-11-23 09:25AM
Mar-10-23 02:32AM
Mar-09-23 07:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Feb-14-23 09:50AM
Feb-13-23 05:00PM
Feb-08-23 02:27PM
Jan-27-23 07:00AM
Jan-11-23 07:00AM
Dec-27-22 07:34AM
Dec-22-22 07:00AM
Dec-19-22 07:00AM
Dec-15-22 04:45PM
Dec-06-22 09:53AM
Dec-02-22 06:02PM
Dec-01-22 07:00AM
Nov-30-22 07:00AM
Nov-20-22 09:45AM
Nov-14-22 07:00AM
Nov-10-22 07:00AM
Oct-27-22 07:00AM
Oct-05-22 07:00AM
Sep-19-22 10:10AM
Sep-07-22 07:00AM
Aug-12-22 06:40AM
Aug-09-22 07:00AM
Aug-03-22 07:00AM
Aug-01-22 07:00AM
Jul-26-22 07:00AM
Jul-20-22 07:49AM
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehta VimalCEO and PresidentJun 16Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 16Sale20.1830,000605,50139,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15Sale21.5430,000646,22639,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentMay 22Sale25.796,500167,64137,294May 24 04:37 PM
Steinhart Richard IChief Financial OfficerMay 15Sale27.175,000135,8641,500May 16 08:32 PM
Rodriguez JavierSee RemarksMay 15Sale27.321,78548,7654,350May 16 08:29 PM
Nandabalan KrishnanDirectorApr 06Option Exercise0.4160,00024,60060,000Apr 10 06:20 PM
Nandabalan KrishnanDirectorApr 06Sale17.3260,0001,039,2000Apr 10 06:20 PM
Mehta VimalCEO and PresidentMar 21Option Exercise0.4130,00012,30045,894Mar 22 07:30 PM
Mehta VimalCEO and PresidentMar 21Sale19.7130,000591,40515,894Mar 22 07:30 PM
Mehta VimalCEO and PresidentMar 20Option Exercise0.4130,00012,30050,394Mar 22 07:30 PM
Mehta VimalCEO and PresidentMar 20Sale18.3234,500631,90815,894Mar 22 07:30 PM
Steinhart Richard IChief Financial OfficerMar 15Sale19.502,08440,6381,500Mar 16 06:02 PM
Yocca FrankChief Scientific OfficerMar 15Sale19.6998519,3969,496Mar 16 06:01 PM
Rodriguez JavierSee RemarksMar 15Sale19.6295018,6441,135Mar 16 05:58 PM
O'Neill VincentChief Medical OfficerMar 15Sale19.7084516,6421,239Mar 16 05:59 PM